NASDAQ:APRE Aprea Therapeutics (APRE) Stock Price, News & Analysis → [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad) Free APRE Stock Alerts $4.77 +0.16 (+3.47%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$4.50▼$4.7750-Day Range$4.57▼$6.6952-Week Range$2.78▼$8.85Volume5,197 shsAverage Volume10,133 shsMarket Capitalization$25.90 millionP/E RatioN/ADividend YieldN/APrice Target$15.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Aprea Therapeutics alerts: Email Address Aprea Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside224.9% Upside$15.50 Price TargetShort InterestHealthy0.68% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.74Based on 5 Articles This WeekInsider TradingAcquiring Shares$71,952 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.57) to ($0.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.54 out of 5 starsMedical Sector284th out of 928 stocksPharmaceutical Preparations Industry125th out of 437 stocks 3.5 Analyst's Opinion Consensus RatingAprea Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAprea Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Aprea Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.68% of the float of Aprea Therapeutics has been sold short.Short Interest Ratio / Days to CoverAprea Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aprea Therapeutics has recently decreased by 64.28%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAprea Therapeutics does not currently pay a dividend.Dividend GrowthAprea Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APRE. Previous Next 2.6 News and Social Media Coverage News SentimentAprea Therapeutics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Aprea Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Aprea Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aprea Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $71,952.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.80% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.19% of the stock of Aprea Therapeutics is held by institutions.Read more about Aprea Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aprea Therapeutics are expected to grow in the coming year, from ($2.57) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aprea Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aprea Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAprea Therapeutics has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aprea Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening.Click here for all the details… About Aprea Therapeutics Stock (NASDAQ:APRE)Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Read More APRE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APRE Stock News HeadlinesMay 29 at 7:19 PM | msn.comAprea Therapeutics Advances Cancer Treatment Trial to Higher Dose LevelMay 29 at 4:10 AM | americanbankingnews.comAprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 64.3% in MayMay 28, 2024 | globenewswire.comAprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical TrialMay 15, 2024 | msn.comAprea Therapeutics Announces Positive First Quarter Developments and FDA Clearance for Cancer Drug TrialsMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed: Aprea Therapeutics’ Financial and Clinical ProgressMay 14, 2024 | investorplace.comAPRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024May 14, 2024 | globenewswire.comAprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business UpdateMay 13, 2024 | globenewswire.comAprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare ConferenceMay 2, 2024 | markets.businessinsider.comAprea Therapeutics Appoints Mirza As CMOMay 2, 2024 | finance.yahoo.comAprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | globenewswire.comAprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D.April 26, 2024 | finance.yahoo.comInterim Report - January-March 2024April 12, 2024 | markets.businessinsider.comAprea Therapeutics’ Promising Cancer Drug Candidate Warrants Buy RatingApril 10, 2024 | globenewswire.comAprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024April 3, 2024 | msn.comAprea Therapeutics files to sell 4.39M shares of common stock for holdersMarch 28, 2024 | markets.businessinsider.comAprea Therapeutics: Strong Financials and Promising Clinical Pipeline Support Buy RatingMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed: Aprea Therapeutics Poised for Growth with Strong Pipeline Momentum into 2024March 26, 2024 | investorplace.comAPRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023March 26, 2024 | globenewswire.comAprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business UpdateMarch 20, 2024 | markets.businessinsider.comAprea Therapeutics: Strong Buy Rating on Robust Financials and Promising Drug PipelineMarch 18, 2024 | msn.comAprea Therapeutics Secures Up to $34 Million in Groundbreaking Financing DealMarch 16, 2024 | uk.investing.comAprea Therapeutics CFO buys $7,362 in company stockMarch 16, 2024 | uk.investing.comAprea Therapeutics director buys $50k of company stockMarch 14, 2024 | finance.yahoo.comKarolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 millionMarch 14, 2024 | globenewswire.comKarolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 millionSee More Headlines Receive APRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/01/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:APRE CUSIPN/A CIK1781983 Webwww.aprea.com Phone617-463-9385FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$15.50 High Stock Price Target$20.00 Low Stock Price Target$11.00 Potential Upside/Downside+224.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,290,000.00 Net Margins-1,317.82% Pretax Margin-1,317.82% Return on Equity-56.78% Return on Assets-46.12% Debt Debt-to-Equity RatioN/A Current Ratio11.15 Quick Ratio11.15 Sales & Book Value Annual Sales$580,000.00 Price / Sales44.66 Cash FlowN/A Price / Cash FlowN/A Book Value$5.33 per share Price / Book0.89Miscellaneous Outstanding Shares5,430,000Free Float4,735,000Market Cap$25.90 million OptionableNo Data Beta1.08 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Oren Gilad Ph.D. (Age 56)Co-Founder, CEO, President & Director Comp: $796.95kMr. John P. Hamill CPA (Age 60)Senior VP, CFO, Principal Accounting Officer & Secretary Comp: $610.23kDr. Dansu Li Ph.D.Head of TechnologyDr. Lars B. Abrahmsen Ph.D. (Age 67)Senior VP & Chief Scientific Officer Mr. Brian Wiley (Age 56)Senior Vice President of Corporate Development & Strategy Dr. Michel Afargan Ph.D.Head of Pharmacology DevelopmentMr. Ze'ev Weiss B.Sc. (Age 62)C.P.A., Chief Business Advisor Dr. Nadeem Q. Mirza M.D.M.P.H., Chief Medical OfficerMs. Andrea EpsteinControllerMore ExecutivesKey CompetitorsForte BiosciencesNASDAQ:FBRXCellectar BiosciencesNASDAQ:CLRBBeyondSpringNASDAQ:BYSIClearside BiomedicalNASDAQ:CLSDPMV PharmaceuticalsNASDAQ:PMVPView All CompetitorsInsidersOren GiladBought 2,000 shares on 3/13/2024Total: $14,580.00 ($7.29/share)Bernd R SeizingerBought 6,860 shares on 3/13/2024Total: $50,009.40 ($7.29/share)John P HamillBought 1,010 shares on 3/13/2024Total: $7,362.90 ($7.29/share)Bernd R SeizingerBought 4,068 shares on 6/6/2023Total: $14,766.84 ($3.63/share)View All Insider Transactions APRE Stock Analysis - Frequently Asked Questions Should I buy or sell Aprea Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aprea Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" APRE shares. View APRE analyst ratings or view top-rated stocks. What is Aprea Therapeutics' stock price target for 2024? 2 Wall Street analysts have issued 12 month target prices for Aprea Therapeutics' stock. Their APRE share price targets range from $11.00 to $20.00. On average, they predict the company's stock price to reach $15.50 in the next year. This suggests a possible upside of 224.9% from the stock's current price. View analysts price targets for APRE or view top-rated stocks among Wall Street analysts. How have APRE shares performed in 2024? Aprea Therapeutics' stock was trading at $4.70 at the start of the year. Since then, APRE shares have increased by 1.5% and is now trading at $4.77. View the best growth stocks for 2024 here. Are investors shorting Aprea Therapeutics? Aprea Therapeutics saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 32,400 shares, a decline of 64.3% from the April 30th total of 90,700 shares. Based on an average trading volume of 29,800 shares, the days-to-cover ratio is currently 1.1 days. Currently, 0.7% of the shares of the company are short sold. View Aprea Therapeutics' Short Interest. When is Aprea Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our APRE earnings forecast. How were Aprea Therapeutics' earnings last quarter? Aprea Therapeutics, Inc. (NASDAQ:APRE) announced its earnings results on Tuesday, May, 14th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.11. The business earned $0.38 million during the quarter. Aprea Therapeutics had a negative net margin of 1,317.82% and a negative trailing twelve-month return on equity of 56.78%. When did Aprea Therapeutics' stock split? Shares of Aprea Therapeutics reverse split before market open on Monday, February 13th 2023. The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Aprea Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aprea Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Biogen (BIIB), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Alkermes (ALKS), Allogene Therapeutics (ALLO), Alnylam Pharmaceuticals (ALNY) and Amgen (AMGN). When did Aprea Therapeutics IPO? Aprea Therapeutics (APRE) raised $52 million in an IPO on Thursday, October 3rd 2019. The company issued 5,000,000 shares at $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets served as the underwriters for the IPO. Who are Aprea Therapeutics' major shareholders? Aprea Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bernd R Seizinger, Eyal C Attar, Gregory Alan Korbel, John P Hamill, Lars B Abrahmsen and Oren Gilad. View institutional ownership trends. How do I buy shares of Aprea Therapeutics? Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:APRE) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.